Jazz Pharmaceuticals plc (JAZZ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Core Insights - Jazz Pharmaceuticals experienced record revenue growth of 5% in 2025, marking the 21st consecutive year of growth for the company [3]. Commercial Performance - The revenue growth was primarily driven by a 12% increase in Xywav, a 9% increase in Epidiolex, and strong initial uptake of Modeyso [3]. Future Outlook - The advancements in commercial performance, pipeline development, and corporate strategy in 2025 position the company well for continued success in 2026 [3].